Having worked for ten years in the research department of the CEA’s material sciences, Christophe Bureau created two start-ups based on the technology of electro-grafting in the microelectronic and the biomedical sectors. He raised eight million Euros after three capital pools between 2001 and 2008. AlchiMedics’ technology was used on humans at the end of 2007 and approved in 2010 in China, where the first product was launched in January 2011. Having succeeded in making a profit from a technological innovation, Christophe Bureau is now developing at Becton Dickinson an approach in which innovation is guided by market forces, irrespective of whether there is a real client in view or not, as opposed to an approach driven by technology (‘techno-push’). He is calling for conditions regarding spin-offs in France to change, as currently only techno-push based approaches (which are risky and whose profitability is hard to measure) benefit from the attention and support of institutions and financial backers.
The entire article was written by:
This session was published in issue n°100 of the Journal de l'École de Paris du management, entitled Des mondes s'ouvrent.
This website uses Google Analytics. By continuing to browse, you authorize us to place a cookie for audience measurement purposes.